Private-Sector Innovation Key To Ending TB

STAT: Ending tuberculosis will take continued private-sector innovation
Adrian Thomas, private sector constituency board member for the Stop TB Partnership and vice president for global public health and access at Johnson & Johnson

“…[K]ey debates are happening right now regarding the political declaration that U.N. member states will adopt at the [first-ever] high-level meeting [on tuberculosis (TB) this month]. One of them is focused on — and will have major implications for — how we sustain and encourage innovation against TB. … [W]e need to think creatively if we want major innovator companies to develop tomorrow’s novel TB therapies, diagnostics, vaccines, and cures. At the high-level meeting on TB, the global health community will have a unique opportunity to lay the foundation for a vibrant innovation ecosystem to end TB. Models for pricing and access must be designed to ensure that TB medicines are affordable and accessible to all patients while also encouraging the pharmaceutical industry to identify the treatments of the future. Millions of people around the world … are counting on us to get this right” (8/23).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.